$NRXP
NRX Pharmaceuticals, Inc.

2023 Q1 Form 10-K Financial Statement

#000155837023005292 Filed on March 31, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.785M $5.432M $27.31M
YoY Change -43.41% -88.33% -63.56%
% of Gross Profit
Research & Development $3.650M $4.456M $17.03M
YoY Change -33.43% -30.52% -15.95%
% of Gross Profit
Depreciation & Amortization $1.000K $1.000K $4.000K
YoY Change 0.0% 156.41% 100.0%
% of Gross Profit
Operating Expenses $9.435M $9.888M $44.34M
YoY Change -39.92% -81.33% -61.71%
Operating Profit -$9.435M -$44.34M
YoY Change -39.92% -61.71%
Interest Expense $168.0K $152.0K $504.0K
YoY Change 5500.0% -68.42% 2700.0%
% of Operating Profit
Other Income/Expense, Net -$1.604M -$505.0K $4.581M
YoY Change -171.07% -102.33% -79.85%
Pretax Income -$11.04M -$10.24M -$39.75M
YoY Change -17.91% -66.74% -57.28%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$11.04M -$10.24M -$39.75M
YoY Change -17.91% -66.74% -57.28%
Net Earnings / Revenue
Basic Earnings Per Share -$0.16 -$0.60
Diluted Earnings Per Share -$0.16 -$0.15 -$0.60
COMMON SHARES
Basic Shares Outstanding 71.56M 67.64M 65.77M
Diluted Shares Outstanding 67.45M 65.77M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $16.51M $20.05M $20.05M
YoY Change -58.94% -27.35% -27.35%
Cash & Equivalents $16.51M $20.05M
Short-Term Investments
Other Short-Term Assets $5.250M $5.741M $5.741M
YoY Change 55.23% 12.37% 12.37%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $21.76M $25.80M $25.80M
YoY Change -50.08% -21.15% -21.15%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $24.00K $21.00K $21.00K
YoY Change 41.18% 40.0% 40.0%
Total Long-Term Assets $24.00K $21.00K $21.00K
YoY Change 41.18% 40.0% 40.0%
TOTAL ASSETS
Total Short-Term Assets $21.76M $25.80M $25.80M
Total Long-Term Assets $24.00K $21.00K $21.00K
Total Assets $21.78M $25.82M $25.82M
YoY Change -50.05% -21.12% -21.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.776M $2.076M $2.076M
YoY Change -12.41% -43.69% -43.69%
Accrued Expenses $5.054M $4.855M $4.513M
YoY Change 26.32% 104.42% 176.53%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $12.19M $7.703M $7.703M
YoY Change 2244.04% 1387.07% 1387.07%
Total Short-Term Liabilities $22.06M $15.59M $15.59M
YoY Change 85.22% 30.71% 30.71%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $2.822M $2.822M
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $2.822M $2.822M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $22.06M $15.59M $15.59M
Total Long-Term Liabilities $0.00 $2.822M $2.822M
Total Liabilities $22.06M $18.41M $18.41M
YoY Change 85.22% 54.38% 54.38%
SHAREHOLDERS EQUITY
Retained Earnings -$234.0M -$223.0M
YoY Change 18.99% 21.69%
Common Stock $70.00K $67.00K
YoY Change 4.48% 13.56%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$284.0K $7.409M $7.409M
YoY Change
Total Liabilities & Shareholders Equity $21.78M $25.82M $25.82M
YoY Change -50.05% -21.12% -21.12%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$11.04M -$10.24M -$39.75M
YoY Change -17.91% -66.74% -57.28%
Depreciation, Depletion And Amortization $1.000K $1.000K $4.000K
YoY Change 0.0% 156.41% 100.0%
Cash From Operating Activities -$6.089M -$8.318M -$39.76M
YoY Change -41.34% -26.26% 5.44%
INVESTING ACTIVITIES
Capital Expenditures $4.000K -$1.000K $10.00K
YoY Change -233.33% 156.41% -242.86%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$4.000K $1.000K -$10.00K
YoY Change 33.33% -356.41% 42.86%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.545M 10.12M 32.21M
YoY Change -88.93% 822826.83% -49.23%
NET CHANGE
Cash From Operating Activities -6.089M -8.318M -39.76M
Cash From Investing Activities -4.000K 1.000K -10.00K
Cash From Financing Activities 2.545M 10.12M 32.21M
Net Change In Cash -3.548M 1.805M -7.551M
YoY Change -128.17% -116.0% -129.33%
FREE CASH FLOW
Cash From Operating Activities -$6.089M -$8.318M -$39.76M
Capital Expenditures $4.000K -$1.000K $10.00K
Free Cash Flow -$6.093M -$8.317M -$39.77M
YoY Change -41.28% -26.26% 5.49%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
65766786
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46917701
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001719406
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Entity Registrant Name
EntityRegistrantName
NRX Pharmaceuticals, Inc.
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58810550
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
66442989
CY2022 nrxp Class Of Warrant Or Right Weighted Average Remaining Contractual Term Expired
ClassOfWarrantOrRightWeightedAverageRemainingContractualTermExpired
P2Y7M13D
CY2021 nrxp Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term Forfeited
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermForfeited
P0Y0M0D
CY2021 nrxp Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Exercised
P0Y0M0D
CY2022 nrxp Share Based Compensation Arrangement By Share Based Payment Award Options Expirations Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsWeightedAverageRemainingContractualTerm
P0Y0M0D
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-38302
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-2844431
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
1201 Orange Street
CY2022 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 600
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Wilmington
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
DE
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19801
CY2022 dei City Area Code
CityAreaCode
484
CY2022 dei Local Phone Number
LocalPhoneNumber
254-6134
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Public Float
EntityPublicFloat
34952532000000
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
71557580
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20054000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27605000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5741000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5109000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
25795000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
32714000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
21000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
15000
CY2022Q4 us-gaap Assets
Assets
25816000
CY2021Q4 us-gaap Assets
Assets
32729000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2076000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3687000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4855000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2375000
CY2022Q4 nrxp Accrued Clinical Site Costs
AccruedClinicalSiteCosts
914000
CY2021Q4 nrxp Accrued Clinical Site Costs
AccruedClinicalSiteCosts
469000
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
4582000
CY2022Q4 nrxp Convertible Notes Payable Accrued Interest
ConvertibleNotesPayableAccruedInterest
7703000
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
37000
CY2021Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
292000
CY2021Q4 nrxp Notes Payable And Accrued Interest Current
NotesPayableAndAccruedInterestCurrent
518000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15585000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11923000
CY2022Q4 nrxp Notes Payable And Accrued Interest Non Current
NotesPayableAndAccruedInterestNonCurrent
2822000
CY2022Q4 us-gaap Liabilities
Liabilities
18407000
CY2021Q4 us-gaap Liabilities
Liabilities
11923000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-7.44
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
66442989
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58810550
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
67000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
59000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
230339000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
203990000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-222997000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-183243000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
7409000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
20806000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
25816000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
32729000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17027000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20257000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
27308000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
74944000
CY2021 nrxp Settlement Expense
SettlementExpense
21366000
CY2021 nrxp Expense Reimbursement
ExpenseReimbursement
771000
CY2022 us-gaap Operating Expenses
OperatingExpenses
44335000
CY2021 us-gaap Operating Expenses
OperatingExpenses
115796000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-44335000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-115796000
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
121000
CY2022 us-gaap Interest Income Other
InterestIncomeOther
249000
CY2021 us-gaap Interest Expense
InterestExpense
18000
CY2022 nrxp Increase Decrease In Fair Value Of Convertible Debt
IncreaseDecreaseInFairValueOfConvertibleDebt
-505000
CY2022 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
255000
CY2021 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
1692000
CY2022 nrxp Gain Loss On Fair Value Of Cash Earnout Liability
GainLossOnFairValueOfCashEarnoutLiability
4582000
CY2021 nrxp Gain Loss On Fair Value Of Cash Earnout Liability
GainLossOnFairValueOfCashEarnoutLiability
20938000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4581000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
22733000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-39754000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-93063000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-39754000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-93063000
CY2021 nrxp Deemed Dividend Warrants
DeemedDividendWarrants
255822000
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-39754000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-348885000
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.60
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.98
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.60
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.98
CY2022 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.60
CY2022 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.60
CY2021 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-7.44
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65766786
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46917701
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-43771000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
9624000
CY2021 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
60852000
CY2021 nrxp Net Of Redemptions And Issuance Costs
NetOfRedemptionsAndIssuanceCosts
1413000
CY2021 nrxp Stock Repurchased During Period Value Merger And Recapitalization Net Of Redemptions And Issuance Costs
StockRepurchasedDuringPeriodValueMergerAndRecapitalizationNetOfRedemptionsAndIssuanceCosts
26616000
CY2021 nrxp Financing Net Of Issuance Costs
FinancingNetOfIssuanceCosts
1900000
CY2021 nrxp Stock Issued During Period Value New Issues From Private Investment In Equity
StockIssuedDuringPeriodValueNewIssuesFromPrivateInvestmentInEquity
8100000
CY2021 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
4850000
CY2021 nrxp Adjustments To Additional Paid In Capital Modifications Of Stock Options Due To Business Combination
AdjustmentsToAdditionalPaidInCapitalModificationsOfStockOptionsDueToBusinessCombination
1015000
CY2021 nrxp Adjustments To Additional Paid In Capital Modifications Of Warrant Issued Due To Business Combination
AdjustmentsToAdditionalPaidInCapitalModificationsOfWarrantIssuedDueToBusinessCombination
2330000
CY2021 nrxp Sale Of Stock And Warrants Issuance Costs
SaleOfStockAndWarrantsIssuanceCosts
3669000
CY2021 nrxp Common Stock And Warrants Issued In Private Placement Net Of Issuance Costs
CommonStockAndWarrantsIssuedInPrivatePlacementNetOfIssuanceCosts
27359000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
16699000
CY2021 nrxp Stock Issued For Payment Of Consulting Services
StockIssuedForPaymentOfConsultingServices
48987000
CY2021 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
4440000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-93063000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
20806000
CY2022 nrxp Sale Of Stock And Warrants Issuance Costs
SaleOfStockAndWarrantsIssuanceCosts
2283000
CY2022 nrxp Common Stock And Warrants Issued In Private Placement Net Of Issuance Costs
CommonStockAndWarrantsIssuedInPrivatePlacementNetOfIssuanceCosts
22702000
CY2022 nrxp Stock Issued For Payment Of Consulting Services
StockIssuedForPaymentOfConsultingServices
17000
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10000
CY2022 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3628000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-39754000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
7409000
CY2022 us-gaap Profit Loss
ProfitLoss
-39754000
CY2021 us-gaap Profit Loss
ProfitLoss
-93063000
CY2022 us-gaap Depreciation
Depreciation
4000
CY2021 us-gaap Depreciation
Depreciation
2000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
3628000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
7785000
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
121000
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-255000
CY2021 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1692000
CY2022 nrxp Gain Loss On Fair Value Of Cash Earnout Liability
GainLossOnFairValueOfCashEarnoutLiability
4582000
CY2021 nrxp Gain Loss On Fair Value Of Cash Earnout Liability
GainLossOnFairValueOfCashEarnoutLiability
20938000
CY2022 nrxp Increase Decrease In Fair Value Of Convertible Debt
IncreaseDecreaseInFairValueOfConvertibleDebt
-505000
CY2021 us-gaap Paid In Kind Interest
PaidInKindInterest
19000
CY2021 nrxp Noncash Settlement Expense
NoncashSettlementExpense
21366000
CY2021 nrxp Non Cash Consulting Expense
NonCashConsultingExpense
53837000
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-831000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
632000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4809000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1611000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-19000
CY2022 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2942000
CY2021 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-901000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-39755000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37703000
CY2022 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
10000
CY2021 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
7000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7000
CY2022 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
10020000
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
10000
CY2021 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
16699000
CY2021 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
11050000
CY2021 nrxp Proceeds From Issuance Of Common Stock And Exercise Of Stock Options
ProceedsFromIssuanceOfCommonStockAndExerciseOfStockOptions
9624000
CY2022 us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
-518000
CY2022 nrxp Net Proceeds From Payments For Issuance Of Common Stock And Warrants In Private Placement Net Of Issuance Costs
NetProceedsFromPaymentsForIssuanceOfCommonStockAndWarrantsInPrivatePlacementNetOfIssuanceCosts
22702000
CY2021 nrxp Net Proceeds From Payments For Issuance Of Common Stock And Warrants In Private Placement Net Of Issuance Costs
NetProceedsFromPaymentsForIssuanceOfCommonStockAndWarrantsInPrivatePlacementNetOfIssuanceCosts
27359000
CY2021 nrxp Proceeds From Repayments Of Notes Payable Assumed In Merger
ProceedsFromRepaymentsOfNotesPayableAssumedInMerger
-1100000
CY2021 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
-176000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
32214000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
63456000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-7551000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
25746000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27605000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1859000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20054000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27605000
CY2021 nrxp Reclassification Of Settlement Liability Upon Issuance Of Warrant
ReclassificationOfSettlementLiabilityUponIssuanceOfWarrant
60852000
CY2022 nrxp Issuance Of Common Stock Warrants As Offering Costs
IssuanceOfCommonStockWarrantsAsOfferingCosts
726000
CY2021 nrxp Issuance Of Common Stock Warrants As Offering Costs
IssuanceOfCommonStockWarrantsAsOfferingCosts
1027000
CY2021 nrxp Extinguishment Of Paycheck Protection Program Loan
ExtinguishmentOfPaycheckProtectionProgramLoan
121000
CY2022 us-gaap Stock Issued1
StockIssued1
17000
CY2022Q4 us-gaap Cash
Cash
20100000
CY2022Q4 nrxp Prepaid Clinical Development Expenses
PrepaidClinicalDevelopmentExpenses
1966000
CY2021Q4 nrxp Prepaid Clinical Development Expenses
PrepaidClinicalDevelopmentExpenses
512000
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in its financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s financial statements relate to the convertible note payable, Earnout Cash liability, valuation of common and preferred stock, stock options, warrants, and the valuation allowance of deferred tax assets resulting from net operating losses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected. </p>
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk and Off-Balance Sheet Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash equivalents are occasionally invested in certificates of deposit. The Company maintains each of its cash balances with high-quality and accredited financial institutions and accordingly, such funds are not exposed to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company maintains a portion of its cash and cash equivalent balances in the form of a money market account with a financial institution that management believes to be creditworthy. </p>
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
331000
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
345000
CY2022Q4 nrxp Prepaid Legal Expenses
PrepaidLegalExpenses
270000
CY2022Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
7000
CY2021Q4 nrxp Prepaid Manufacturing Expenses Current
PrepaidManufacturingExpensesCurrent
1028000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5741000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
3167000
CY2022 nrxp Option Exchange Ratio Shares Earnout Shares For Common Stockholders
OptionExchangeRatioSharesEarnoutSharesForCommonStockholders
22209280
CY2022 nrxp Option Exchange Ratio Value Earnout Cash For Common Stockholders
OptionExchangeRatioValueEarnoutCashForCommonStockholders
88800000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
3224000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5109000
CY2022Q4 nrxp Other Accrued Expenses Current
OtherAccruedExpensesCurrent
2616000
CY2021Q4 nrxp Other Accrued Expenses Current
OtherAccruedExpensesCurrent
121000
CY2022Q4 nrxp Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
974000
CY2021Q4 nrxp Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
1055000
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
923000
CY2021Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
456000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
342000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
743000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4855000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2375000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022 nrxp Common Stock And Warrants Issued In Private Placement Number Of Shares
CommonStockAndWarrantsIssuedInPrivatePlacementNumberOfShares
7824727
CY2022 nrxp Net Proceeds From Payments For Issuance Of Common Stock And Warrants In Private Placement Net Of Issuance Costs
NetProceedsFromPaymentsForIssuanceOfCommonStockAndWarrantsInPrivatePlacementNetOfIssuanceCosts
22700000
CY2022 nrxp Common Stock Shares Issued New Issuance And Sale Of Options And Warrants
CommonStockSharesIssuedNewIssuanceAndSaleOfOptionsAndWarrants
49605
CY2022 nrxp Proceeds From Sale Of Stock New Issuances And Sale Of Stock Options And Warrants
ProceedsFromSaleOfStockNewIssuancesAndSaleOfStockOptionsAndWarrants
100000
CY2021 nrxp Issuance Of Stock For Exercise Of Warrants And Option
IssuanceOfStockForExerciseOfWarrantsAndOption
16700000
CY2021 nrxp Shares Of Stock Issued For Payment Of Consulting Services
SharesOfStockIssuedForPaymentOfConsultingServices
4834045
CY2021 nrxp Contingent Earnout Shares Excluded From Eps Computation
ContingentEarnoutSharesExcludedFromEpsComputation
1044453
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021 nrxp Gross Proceeds From Exercise Of Warrants
GrossProceedsFromExerciseOfWarrants
100000
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3075470
CY2020 nrxp Class Of Warrant Or Right Weighted Average Remaining Contractual Term2
ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm2
P4Y4M2D
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.09
CY2020Q4 nrxp Class Of Warrant Or Right Outstanding Intrinsic Value
ClassOfWarrantOrRightOutstandingIntrinsicValue
150956000
CY2021 nrxp Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
6193449
CY2021 nrxp Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm
P1Y10M24D
CY2021 nrxp Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Issued
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued
4.62
CY2021 nrxp Class Of Warrant Or Right Granted Intrinsic Value
ClassOfWarrantOrRightGrantedIntrinsicValue
115941000
CY2021 nrxp Class Of Warrant Or Right Assumed
ClassOfWarrantOrRightAssumed
3586250
CY2021 nrxp Class Of Warrant Or Rights Assumed In Period Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightsAssumedInPeriodWeightedAverageRemainingContractualTerm
P5Y
CY2021 nrxp Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Assumed
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAssumed
-11.50
CY2021 nrxp Class Of Warrant Or Right Assumed Intrinsic Value
ClassOfWarrantOrRightAssumedIntrinsicValue
45725000
CY2021 nrxp Warrants Exercised During Period
WarrantsExercisedDuringPeriod
3330956
CY2021 nrxp Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Assumed Exercised
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAssumedExercised
3.19
CY2021 nrxp Warrants Exercised Aggregate Intrinsic Value
WarrantsExercisedAggregateIntrinsicValue
67412000
CY2021 nrxp Class Of Warrant Or Right Forfeited
ClassOfWarrantOrRightForfeited
218423
CY2021 nrxp Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Cancelled
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCancelled
1.53
CY2021 nrxp Warrants Canceled Or Forfeited Aggregate Intrinsic Value
WarrantsCanceledOrForfeitedAggregateIntrinsicValue
1501000
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
9305790
CY2021 nrxp Class Of Warrant Or Right Weighted Average Remaining Contractual Term2
ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm2
P3Y7M13D
CY2021Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
9.09
CY2021Q4 nrxp Class Of Warrant Or Right Outstanding Intrinsic Value
ClassOfWarrantOrRightOutstandingIntrinsicValue
4942000
CY2022 nrxp Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
8215963
CY2022 nrxp Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm
P5Y6M
CY2022 nrxp Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Issued
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued
3.11
CY2022 nrxp Class Of Warrant Or Right Expired
ClassOfWarrantOrRightExpired
1036830
CY2022 nrxp Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Expired
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired
3.05
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
16484923
CY2022 nrxp Class Of Warrant Or Right Weighted Average Remaining Contractual Term2
ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm2
P3Y7M2D
CY2022Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
6.49
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2414303
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.17
CY2020 nrxp Share Based Compensation Arrangement Options Outstanding Weighted Average Remaining Contractual Term2
ShareBasedCompensationArrangementOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y2M12D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
53660000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
892224
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
13.95
CY2021 nrxp Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Granted
P9Y10M24D
CY2021 nrxp Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueGranted
3825000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
390187
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.73
CY2021 nrxp Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Forfeited
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueForfeited
7562000
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
516025
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.23
CY2021 nrxp Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueExercised
-3645000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2400315
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.28
CY2021 nrxp Share Based Compensation Arrangement Options Outstanding Weighted Average Remaining Contractual Term2
ShareBasedCompensationArrangementOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M18D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
4224000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1844640
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.45
CY2022 nrxp Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Granted
P9Y4M24D
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
742736
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.66
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
903765
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
5.79
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
49605
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.20
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2548849
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.20
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2549000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
863746
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
4.75
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P6Y3M18D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
148000
CY2022Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2200000
CY2022 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y7M6D
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3628000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7785000
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
-0.0008
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
0.0005
CY2022 nrxp Effective Income Tax Rate Reconciliation Fair Market Value Earnout
EffectiveIncomeTaxRateReconciliationFairMarketValueEarnout
0.0242
CY2021 nrxp Effective Income Tax Rate Reconciliation Fair Market Value Earnout
EffectiveIncomeTaxRateReconciliationFairMarketValueEarnout
0.0472
CY2022 nrxp Effective Income Tax Rate Reconciliation Settlement Warrants
EffectiveIncomeTaxRateReconciliationSettlementWarrants
0.0000
CY2021 nrxp Effective Income Tax Rate Reconciliation Settlement Warrants
EffectiveIncomeTaxRateReconciliationSettlementWarrants
0.1335
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.0001
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.0002
CY2022 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.0033
CY2021 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.0000
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0162
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0005
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.2464
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.1262
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.0013
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000
CY2022 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-9295000
CY2021 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-11709000
CY2022 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
133000
CY2021 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-5000
CY2022 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-647000
CY2021 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-42000
CY2022 us-gaap Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability
IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
9809000
CY2021 us-gaap Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability
IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
11756000
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
33640000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
28053000
CY2022Q4 nrxp Deferred Tax Assets Common Stock Warrants
DeferredTaxAssetsCommonStockWarrants
1894000
CY2021Q4 nrxp Deferred Tax Assets Common Stock Warrants
DeferredTaxAssetsCommonStockWarrants
1876000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
134000
CY2022Q4 nrxp Deferred Tax Assets174 Capitalization
DeferredTaxAssets174Capitalization
3410000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2411000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1584000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
202000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
100000
CY2022Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
500000
CY2021Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
500000
CY2022Q4 nrxp Deferred Tax Liabilities Depreciation
DeferredTaxLiabilitiesDepreciation
3000
CY2021Q4 nrxp Deferred Tax Liabilities Depreciation
DeferredTaxLiabilitiesDepreciation
2000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
42054000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
32245000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
42054000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
32245000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2022 nrxp Unrecognized Tax Benefits Decrease In Deferred Tax Asset
UnrecognizedTaxBenefitsDecreaseInDeferredTaxAsset
500000
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0.0
CY2022Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0.0
CY2021 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0.0
CY2022 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0.0
CY2021Q4 us-gaap Accounts Payable Related Parties Current And Noncurrent
AccountsPayableRelatedPartiesCurrentAndNoncurrent
100000
CY2023Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
2900000
CY2023Q1 nrxp Related Party Minimum Performance Based Annual Bonus
RelatedPartyMinimumPerformanceBasedAnnualBonus
250000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
500000
CY2022 dei Auditor Name
AuditorName
KPMG LLP
CY2022 dei Auditor Location
AuditorLocation
Short Hills, NJ
CY2022 dei Auditor Firm
AuditorFirmId
185

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
nrxp-20221231_cal.xml Edgar Link unprocessable
0001558370-23-005292-index-headers.html Edgar Link pending
0001558370-23-005292-index.html Edgar Link pending
0001558370-23-005292.txt Edgar Link pending
0001558370-23-005292-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nrxp-20221231.xsd Edgar Link pending
nrxp-20221231x10k.htm Edgar Link pending
nrxp-20221231x10k001.jpg Edgar Link pending
nrxp-20221231x10k002.jpg Edgar Link pending
nrxp-20221231x10k003.jpg Edgar Link pending
nrxp-20221231x10k004.jpg Edgar Link pending
nrxp-20221231x10k005.jpg Edgar Link pending
nrxp-20221231x10k006.jpg Edgar Link pending
nrxp-20221231x10k007.jpg Edgar Link pending
nrxp-20221231x10k008.jpg Edgar Link pending
nrxp-20221231x10k009.jpg Edgar Link pending
nrxp-20221231x10k010.jpg Edgar Link pending
nrxp-20221231x10k011.jpg Edgar Link pending
nrxp-20221231xex10d53.htm Edgar Link pending
nrxp-20221231xex23d1.htm Edgar Link pending
nrxp-20221231xex31d1.htm Edgar Link pending
nrxp-20221231xex31d2.htm Edgar Link pending
nrxp-20221231xex32d1.htm Edgar Link pending
nrxp-20221231xex32d2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
nrxp-20221231_def.xml Edgar Link unprocessable
nrxp-20221231_lab.xml Edgar Link unprocessable
nrxp-20221231_pre.xml Edgar Link unprocessable
nrxp-20221231x10k_htm.xml Edgar Link completed
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending